Arecor Appoints Dr. Sarah Howell as Chief Operating OfficerBy Arecor, PRNE
Wednesday, November 9, 2011
CAMBRIDGE, England, November 10, 2011 -
Arecor, the leading company in advancing aqueous formulation solutions for proteins, peptides and vaccines, is pleased to announce the appointment of Dr Sarah Howell as Chief Operating Officer. Dr Howell will be responsible for the operations of Arecor, with a focus on developing and maintaining Arecor’s upward growth curve ensuring the company continues to deliver exceptional formulation solutions and performance to the highest standards across the industry.
Dr Howell has a strong background in clinical and commercial pharmaceutical product development, manufacture, supply and licensing across a range of products and therapeutic areas having worked in a number of leading roles in the pharmaceutical industry, most recently as Vice President for CMC (Chemistry, Manufacturing & Controls) and Technical Development for BTG where she had responsibility for CMC development and supply across BTG’s diverse portfolio of products. Previously she held senior roles in product development and manufacturing for UCB-Celltech and GlaxoSmithKline. She is also an active member of the BioIndustry Association (BIA) Manufacturing Advisory Committee. Dr Howell has an honours degree in Chemistry from the University of Birmingham and a PhD in Physical Organic Chemistry from the University of St Andrews.
Tom Saylor, CEO of Arecor stated “Sarah’s considerable technical and leadership experience in the management of development programmes for biologic drugs, and her capabilities in building partnerships with major pharmaceutical companies will be a tremendous asset to Arecor as it expands its business in an industry looking to formulation as an enabling technology for the new generation of biologic drugs.”
Arecor was established to provide formulation solutions to pharmaceutical and biotech companies developing proteins, vaccines and diagnostics based upon new insights into stabilization of biologics. Proteins and vaccines are often fragile entities, and stability can represent significant constraints in the development of new products and extending the use of existing products. Arecor has developed Arestat™, a patented set of tools for stabilization which address the main pathways of degradation. As a simple reformulation, Arestat™ can be readily incorporated into standard manufacturing practice, without covalent modification of the biologic and using excipients approved for the route of delivery. Arecor currently has active feasibility programs and licenses with many of the top pharmaceutical and biotech companies on a wide range of proteins and vaccines.
Tom Saylor, CEO email@example.com
2 Cambridge Science Park
Tags: Arecor, Cambridge, England, November 10, United Kingdom